TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Methionine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Taurine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieving goal blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maintenance of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recidivism of self-injurious behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic in‐segment late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In‐segment binary angiographic restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In‐hospital major adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in triglyceride (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HDL cholesterol (HDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight loss during RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitrate-mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: WOMAC index percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Duration of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Re-epithelialisation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain during dressing procedures
Endpoint domain: Adverse events/effects
Primary endpoint: binge eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deposition of radioactivity in the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Osteoporotic Vertebral Compression Fractures (OVCF)
Endpoint domain: Adverse events/effects
Primary endpoint: global rating of improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incontinence-specific HRQOL outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: generic preference-based HRQOL outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Longitudinal changes in rFTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of soluble VCAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Levels of soluble P‐selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Agreement between clinical probability and lung-scan result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain/distress from the ROP screening exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability of orthodontic mini-screw implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated haemoglobin A1c profiles
Endpoint domain: Physiological/clinical
Primary endpoint: Uncorrected Visual Acuity (UCVA) 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean refractive cylinder change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity at highest spatial frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal working capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased tolerance to oral peanut challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased sensitivity on titrated skin prick testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic reactions during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of hypoaminoacidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in essential AAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in nonessential AAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction with consent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Free recall performance under cognitive load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived mental fatigue during high cognitive load assessment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Teaching time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sera interleukin-2 and interferon-gamma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative endoscopic relapse rates
Endpoint domain: Mortality/survival
Primary endpoint: General Depression scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptability in BPD patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: early drop-out rates
Endpoint domain: Adverse events/effects
Primary endpoint: Single procedure success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing peritonitis within 30 days after ESI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of intrauterine abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep duration and quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of varices
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of variceal hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: sensitivity for invasive epithelial ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sensitivity for type II cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response to infant's distress subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of mothers terminating feeding when infant shows satiation cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatology scores (SNOT‐20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lund Mackay scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average DLMO advances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of confirmed, symptomatic hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Liver stiffness measurement (LSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controlled attenuation parameter (CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-m on-ice sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of high-risk children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukocyte gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean serum levels of osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean BAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mycologic cure of toenail onychomycosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: doctor/patient communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean pre‐dose FEV1 at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time to onset of action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in urinary symptoms (Boyarsky score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity counts per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free status after 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Staphylococcus aureus and Pityrosporum ovale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: decrease in depression, anxiety, and stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in emotion regulation scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of disease measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with community care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration until ready for surgical therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total troponin T release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average number of hospital days per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: AVR (Arterial Vessel Reactivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression severity reduction (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle mass and strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum progesterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lesions detected in the duodenal bulb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of targeted biopsies possible after intravital staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: minor vascular complications at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate treatment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overuse of chloroquine
Endpoint domain: Adverse events/effects
Primary endpoint: perilaryngeal leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LATCH score assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body avoidance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrent myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Severity of neonatal abstinence syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of neonatal abstinence syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment initiation time for neonatal abstinence syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological confirmation of OO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood total glutathione level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gingival indices reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident chlamydia infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: manual boluses required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: i-ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: p-ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to pregnancy (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: freedom from TVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of methicillin‐resistant Staphylococcus aureus
Endpoint domain: Adverse events/effects
Primary endpoint: percentage increase in jeopardized myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptom resolution by day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trust in transplantation as a safe treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in technical knowledge regarding organ donation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Median time to fever resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of infants with concentrations > or =1.0 microg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean arterial pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LII (Lateral Incisor Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMW‐Ad increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TNF‐alpha decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gains in clinical attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal triglyceridaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HAM-D results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of any acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: degree of laser-mediated epithelial ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intracortical facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fewer errors in clinical reasoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HIV-1 RNA levels <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of IV antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence rate after 2 years
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased consistent condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ApoA-1/ApoB ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement rate in CFGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of ERM
Endpoint domain: Adverse events/effects
Primary endpoint: regional cerebral oxygenation (rSO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean number of bed days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total adhesion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of bacteriologically documented infections
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in UI severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall-risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator-free hours at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-assessment for mental fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: efficiency of ventilation (VE/VCO2 slope)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of wound healing complications
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in serum urate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased urinary excretion of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of verinurad
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary heart disease death
Endpoint domain: Mortality/survival
Primary endpoint: Exclusively breastfed at discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exclusively breastfed at 3 months after discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exclusively breastfed at 6 months after discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infant infections
Endpoint domain: Adverse events/effects
Primary endpoint: development of primary mechanical hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness for downward referral
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunosuppression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: perceived physical health impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postprandial hyperglycemia suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in ACQ-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year probability of local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Visualization of the right portal vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality score for the portogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time required to puncture the portal vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propofol EC50 for colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pinch power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC-SOD activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum MDA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean hourly heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24h heart rate increase ≥5 bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: presence of 24h heart rate ≥70 bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24h heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Augmentation Index at 75 bpm (AIx(75))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central Aortic Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesic consumption during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of patients requiring additional analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention